Acetylcysteine
( DrugBank: Acetylcysteine / KEGG DRUG: Acetylcysteine )
21 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 5 |
| 13 | 多発性硬化症／視神経脊髄炎 | 3 |
| 19 | ライソゾーム病 | 4 |
| 20 | 副腎白質ジストロフィー | 1 |
| 21 | ミトコンドリア病 | 1 |
| 49 | 全身性エリテマトーデス | 1 |
| 51 | 全身性強皮症 | 2 |
| 53 | シェーグレン症候群 | 2 |
| 58 | 肥大型心筋症 | 1 |
| 63 | 免疫性血小板減少症 | 1 |
| 85 | 特発性間質性肺炎 | 14 |
6. パーキンソン病
臨床試験数 : 2,586 / 薬物数 : 1,871 - (DrugBank : 354) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
19. ライソゾーム病
臨床試験数 : 990 / 薬物数 : 584 - (DrugBank : 126) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
20. 副腎白質ジストロフィー
臨床試験数 : 68 / 薬物数 : 74 - (DrugBank : 32) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 131
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
21. ミトコンドリア病
臨床試験数 : 94 / 薬物数 : 75 - (DrugBank : 31) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. 全身性エリテマトーデス
臨床試験数 : 1,227 / 薬物数 : 752 - (DrugBank : 175) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. 全身性強皮症
臨床試験数 : 639 / 薬物数 : 551 - (DrugBank : 157) / 標的遺伝子数 : 135 - 標的パスウェイ数 : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
53. シェーグレン症候群
臨床試験数 : 368 / 薬物数 : 277 - (DrugBank : 94) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 186
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
58. 肥大型心筋症
臨床試験数 : 181 / 薬物数 : 136 - (DrugBank : 40) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 187
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. 免疫性血小板減少症
臨床試験数 : 575 / 薬物数 : 261 - (DrugBank : 64) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
85. 特発性間質性肺炎
臨床試験数 : 723 / 薬物数 : 411 - (DrugBank : 126) / 標的遺伝子数 : 104 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
90. 網膜色素変性症
臨床試験数 : 186 / 薬物数 : 191 - (DrugBank : 52) / 標的遺伝子数 : 43 - 標的パスウェイ数 : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
94. 原発性硬化性胆管炎
臨床試験数 : 177 / 薬物数 : 120 - (DrugBank : 48) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 148
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
111. 先天性ミオパチー
臨床試験数 : 10 / 薬物数 : 13 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
164. 眼皮膚白皮症
臨床試験数 : 16 / 薬物数 : 44 - (DrugBank : 27) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
193. プラダー・ウィリ症候群
臨床試験数 : 128 / 薬物数 : 94 - (DrugBank : 25) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
233. ウォルフラム症候群
臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 6) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
296. 胆道閉鎖症
臨床試験数 : 73 / 薬物数 : 67 - (DrugBank : 36) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
298. 遺伝性膵炎
臨床試験数 : 110 / 薬物数 : 142 - (DrugBank : 59) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 154
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. 嚢胞性線維症
臨床試験数 : 1,826 / 薬物数 : 1,271 - (DrugBank : 246) / 標的遺伝子数 : 118 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
337. ホモシスチン尿症
臨床試験数 : 21 / 薬物数 : 22 - (DrugBank : 10) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|